Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1976-1-8
pubmed:abstractText
The oral administration of 0.01% potassium 1-methyl-1,4-dihydro-7-(2-(5-nitrofuryl)vinyl)-4-oxo-1,8-naphthyridine-3-carboxylate (NFN) in ICR/JCL mice resulted in the development of tumors in the lung, forestomach, thymus, and other areas. Special attention was directed to the incidence and growing processes of the pulmonary tumors, which usually exhibited multicentric occurrence. Adenomatous hyperplasia and adenoma were observed in 22.2% of group A (15 approximately 30 weeks), 81.3% of group B (30 approximately 38 weeks), and 91.2% of group C (38 approximately 54 weeks). One case of carcinoma in group B and 5 cases in group C were also found. Most of adenomatous hyperplasia and adenomas developed around 30 weeks after the beginning of administration, whereas the carcinomas developed after 36 weeks. The incidence of tumors was much earlier in females than in males. Further, the tumors were observed to have originated from type B alveolar epithelial cells. The growth of type B alveolar epithelial cells was first noted as an adenomatous hyperplasia along the original alveolar walls, disintegrating and virtually replacing type A alveolar epithelial cells. Accordingly adenoma noduli was formed by these proliferated type B alveolar epithelial cells. Atypical, basophilic cell clusters were found to be present within the adenomas. It was suggested that carcinomas might have originated from these atypical type B alveolar epithelial cells.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0016-450X
pubmed:author
pubmed:issnType
Print
pubmed:volume
66
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
259-67
pubmed:dateRevised
2003-11-14
pubmed:meshHeading
pubmed:year
1975
pubmed:articleTitle
Histogenesis and growing patterns of lung tumors induced by potassium 1-methyl-1,4-dihydro-7-(2-(5-nitrofuryl)vinyl)-4-oxo-1,8-naphthyridine-3-carboxylate in ICR mice.
pubmed:publicationType
Journal Article